These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19042160)

  • 1. The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.
    Farlow MR
    Lancet Neurol; 2009 Jan; 8(1):22-3. PubMed ID: 19042160
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
    Burns A; Bernabei R; Bullock R; Cruz Jentoft AJ; Frölich L; Hock C; Raivio M; Triau E; Vandewoude M; Wimo A; Came E; Van Baelen B; Hammond GL; van Oene JC; Schwalen S
    Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
    Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine].
    Schwalbe O; Wunderlich S; Kloft C
    Med Monatsschr Pharm; 2006 Jun; 29(6):222-4. PubMed ID: 16792199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of galantamine in Alzheimer's disease associated with vascular dementia (according to the study of T. Erkinjuntti group)].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):65-7. PubMed ID: 19938276
    [No Abstract]   [Full Text] [Related]  

  • 6. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
    Jiang D; Yang X; Li M; Wang Y; Wang Y
    J Neural Transm (Vienna); 2015 Aug; 122(8):1157-66. PubMed ID: 25547862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.
    Isik AT; Bozoglu E; Naharci MI; Kilic S
    Am J Geriatr Pharmacother; 2010 Oct; 8(5):454-9. PubMed ID: 21335298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An unusual case of nightmares with galantamine.
    Iraqi A; Hughes TL
    J Am Geriatr Soc; 2009 Mar; 57(3):565. PubMed ID: 19278402
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
    Sano M; Wilcock GK; van Baelen B; Kavanagh S
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease.
    Dev H; Agius M; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):367-9. PubMed ID: 20562785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory myoclonus, a side effect of galantamine.
    Hernández-Fernández F; Pardal-Fernández JM; García-Martínez E; Segura T
    Farm Hosp; 2011; 35(2):97-9. PubMed ID: 21106426
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
    Wong VS
    Neurology; 2007 Aug; 69(8):809; author reply 809-10. PubMed ID: 17709718
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
    Wilcock GK; Lilienfeld S; Gaens E
    BMJ; 2000 Dec; 321(7274):1445-9. PubMed ID: 11110737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease.
    Isik AT; Bozoglu E
    Int Psychogeriatr; 2009 Dec; 21(6):1127-33. PubMed ID: 19631004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine improves gait performance in patients with Alzheimer's disease.
    Assal F; Allali G; Kressig RW; Herrmann FR; Beauchet O
    J Am Geriatr Soc; 2008 May; 56(5):946-7. PubMed ID: 18454755
    [No Abstract]   [Full Text] [Related]  

  • 20. Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany.
    Guo S; Hernandez L; Wasiak R; Gaudig M
    J Med Econ; 2010; 13(4):641-54. PubMed ID: 20958114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.